Chengdu Bright Eye Hospital Co. Ltd. (301239.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Facilities · China · ISIN CNE100005GX3

Price
35.33 CNY
Market cap
5.29 bn CNY
P/E (2025)
–
P/S (2025)
1.89
Dividend yield
0.85 %
Net margin
-2.18 %
Return on equity (ROE)
-2.98 %
Return on assets (ROA)
-1.34 %

Chengdu Bright Eye Hospital Co. Ltd. financials

Fiscal year20242025
Revenue2.68 bn CNY2.80 bn CNY
Gross profit990.45 m CNY1.00 bn CNY
Operating income103.15 m CNY142.64 m CNY
EBIT61.06 m CNY31.85 m CNY
Net income-101.86 m CNY-60.92 m CNY
Diluted EPS – continuing operations-0.68 CNY-0.41 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Chengdu Bright Eye Hospital Co. Ltd.

Bright Eye Hospital Group Co., Ltd., together with its subsidiaries, operates ophthalmic medical institutions in China. The company offers ophthalmic diagnostic and treatment services, including refractive surgery, medical optometry and glasses fitting, cataract surgery, glaucoma treatment, strabismus and amblyopia, pediatric ophthalmology, fundus diseases treatment, oculoplastic surgery, lacrimal duct surgery, and corneal diseases treatment, as well as low vision and visual rehabilitation. It is also involved in medical, hospital, and investment management; ophthalmological research; sale of medical instruments and eyeglasses; cultural propagation; engineering renovation; and technology development. The company was formerly known as Chengdu Bright Eye Hospital Group Co., Ltd. and changed its name to Bright Eye Hospital Group Co., Ltd. in June 2025. Bright Eye Hospital Group Co., Ltd. was founded in 2005 and is headquartered in Chengdu, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 03.11.2026. Details in the risk notice.